In one paragraphArticle in bioRxiv : the preprint server for biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
5 · Who and what moneyAuthors and funding
7 authors.
Haley A BrownDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.ORCID 0000-0003-4229-4863 Adeline L MorrisDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
Nicholas A PudloDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
Ashley E HopkinsDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.
Eric C MartensDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.ORCID 0000-0001-6681-2990 Jonathan L GolobDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.ORCID 0000-0003-0009-5815 Nicole M KoropatkinDepartment of Microbiology and Immunology, University of Michigan Medical School, Ann Arbor, MI 48109, USA.ORCID 0000-0002-2459-3336 Funding
Metabolomics CoreP01HL149633 · NHLBI · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI SCHMIDT, THOMAS M · 2020 to 2024
$11.1MLow dietary fiber and gut microbiota-induced mucus layer erosion as IBD triggersR01DK118024 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI GRACE Y. CHEN, Eric C Martens · 2018 to 2026
$4.9MUnraveling the enzymatic pathway of gut bacterial mucus degradation to treat inflammationR01DK125445 · NIDDK · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KOROPATKIN, NICOLE M, MARTENS, ERIC C · 2020 to 2023
$2.2MAssembly of a model glycan uptake system from a symbiotic human gut bacteriumR01GM118475 · NIGMS · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI KOROPATKIN, NICOLE M · 2016 to 2020
$1.8MThe Influence of the Glucoamylase Inhibitor Acarbose on Bacteroidetes Starch Utilization and Fitness in the Human GutF32AT011278 · NCCIH · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI STEHULAK, HALEY ANN · 2021 to 2022
$139kNCCIH NIH HHS F32 AT011278NHLBI NIH HHS P01 HL149633NIDDK NIH HHS R01 DK118024NIDDK NIH HHS R01 DK125445NIGMS NIH HHS R01 GM118475
6 · The paper itselfAbstract
Acarbose is a type-2 diabetes medicine that inhibits dietary starch breakdown into glucose by inhibiting host amylase and glucosidase enzymes. Numerous gut species in the
Indexed as
acarbosealpha-amylaseBacteroidotaglucosidaseglycoside hydrolase family 13glycoside hydrolase family 97
Identifiers
PMID38826241
PMCPMC11142093
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390